慢性丙型肝炎干扰素抗体及血清分型与派罗欣疗效关系探讨

目的探讨慢性丙型肝炎抗_IFN及血清分型与派罗欣(聚乙二醇IFNα_2a注射液)疗效的关系。方法接受派罗欣治疗的慢性丙型肝炎患者32例,用ELISA法进行血清分型及抗_IFN的测定。结果32例慢性丙型肝炎患者中HCV血清1型、血清2型及血清1 2混合型阳性率分别为50.00%(16/32)、31.25%(10/32)及18.75%(6/32)。32例慢性丙型肝炎患者,总体抗_IFN检出率为53.13%(17/32),其中HCV血清1型、2型及1 2混合型阳性率分别为:31.25%(10/32)、15.63%(5/32)、6.25%(2/32),血清1型与2型相比较差异显著(P<0.05)。派罗欣治疗后,血清2型患者HCVRNA含量<103拷贝/ml,血清1型患者HCVRNA仍>103拷贝/ml。结论32例慢性丙型肝炎患者HCV血清1型为主;派罗欣治疗后血清2型效果优于血清1型。

Correlation between anti-interferon antibodies and serotyping with theraputic effects of PEG-interferon alpha-2a in chronic hepatitis C

Objective To investigate the relations between anti-IFN and different HCV serotypes after the therapy of PEG-IFN alpha-2a in chronic hepatitis C patients. Methods 32 cases were treated with PEG-IFN alpha-2a, serum HCV were typed and the anti-IFN were also monitored by the ELISA methods. Results Of the 32 chronic hepatitis C patients, 50.00% (16/32), 31.25% (10/32) and 18.75%(6/32) were serum type 1, type 2 and mixed-type(1 2) respectively and 53.13% (17/32) patients were anti-IFN positive, in which 31.25%(10/32), 15.63% (5/32) and 6.25%(2/32) belong to serum type 1, type 2 and mixed-types (1 2) respectively. There was a significant difference between type 1 and type 2 in the above patients, P<0.05. After the PEG-IFN alpha-2a treatment, the volume of HCV RNA in the patients of serum type 2 was lower than 103 copy/ml, while the serum type 1 was still higher than 103 copy/ml. Conclusion The serum type 1 is the predominant in 32 hepatitis C patients. The effect in serum 2 is much better than in serum 1 after the therapy of PEG-IFN alpha-2a.